NCT07488923
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07488923
Title A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Acronym SPECTRAL-1
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Moonlight Bio, Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.